Acebilustat - Celtaxsys
Alternative Names: CTX-4430; EP-501Latest Information Update: 12 Jul 2023
At a glance
- Originator Unknown
- Developer Celtaxsys; Stanford University
- Class Anti-inflammatories; Antiacnes; Antifibrotics; Antihypertensives; Antivirals; Skin disorder therapies; Small molecules
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections; Cystic fibrosis; Lymphoedema
- No development reported Bronchiectasis; Pulmonary hypertension; Skin disorders
- Discontinued Acne vulgaris; Hidradenitis suppurativa; Rosacea
Most Recent Events
- 19 May 2023 Efficacy and adverse event data from phase II trial in COVID-19 infections presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 02 Feb 2023 Stanford University completes the phase II trial for COVID-2019 infections (In adults; In the elderly; Combination therapy) in UK (PO, Capsule) (NCT04662086)
- 27 Jul 2022 Phase-II clinical trials in Lymphoedema in USA (PO) (NCT05203835)